What limitations of other atopic dermatitis therapies does ruxolitinib cream address?
Assistant Professor, Director of Center for Eczema and Itch
Northwestern University Feinberg School of Medicine
We've had topical therapies for a long time when it comes to atopic dermatitis, but we've always had some gaps in our care. One big one has been the fact that generally, all of our topicals are pretty broadly acting. So in the case of topical corticosteroids, really, a blunt instrument, and one which has oftentimes has a lot of side effects associated with it. Thinking about thinning of the skin, pigmentary issues, loss of subcutaneous fat, and even potential systemic absorption of steroids as well. In the case of topical calcineurin inhibitors, modest potency and also sometimes adverse events related to actual use themselves in terms of stinging and burning, along with the box warning that at least suggests the potential risk of lymphomas that hasn't been borne out in the long run. For that reason alone, there's been just general desire for a topical therapy that's going to be safe, that's going to be effective, and something that comes in a non-steroid package. And in the case of ruxolitinib cream, it kind of checks all those boxes that you're looking for, potency that rivals some of the stronger topical corticosteroids, and a very nice steroid sparing effect as well, with safety that seems to be borne out both in terms of actual clinical trial data and the real world data as well.
Dr. Raj Chovatiya discusses the limitations of other atopic dermatitis therapies and how ruxolitinib cream addresses these issues. Historically, topical therapies for atopic dermatitis have had some shortcomings. Topical corticosteroids, while effective, are considered a "blunt instrument" and may lead to various side effects, such as thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids.
On the other hand, topical calcineurin inhibitors have modest potency and may cause adverse events like stinging and burning. There has also been concern about a potential risk of lymphomas, although this has not been supported in the long term.
Therefore, there has been a need for a topical therapy that is safe, effective, and non-steroidal. Ruxolitinib cream appears to meet these requirements. It offers potency comparable to some of the stronger topical corticosteroids, and it has a favorable steroid-sparing effect. Furthermore, both clinical trial data and real-world evidence suggest that ruxolitinib cream is a safe option for managing atopic dermatitis. This addresses the limitations of previous therapies and provides a promising treatment alternative for those with the condition.
- Ruxolitinib cream addresses limitations of other atopic dermatitis therapies.
- Traditional topical therapies for atopic dermatitis have some gaps in their care and there is a general desire for a topical therapy that is safe, effective, and non-steroid-based.
- Topical corticosteroids are broadly acting but often associated with side effects like thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids.
- Topical calcineurin inhibitors have modest potency and can cause adverse events such as stinging and burning.
- Ruxolitinib cream offers potency comparable to strong topical corticosteroids and a steroid-sparing effect.
- Ruxolitinib cream's safety has been supported by both clinical trial data and real-world data.